The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jul. 29, 2008
Filed:
Aug. 30, 2000
Francis Joseph Pinto, Mumbai, IN;
Swati Ajay Piramal, Mumbai, IN;
Ram Pratap, Lucknow, IN;
Amiya Prasad Bhaduri, Lucknow, IN;
Harsh Pati Thapliyal, Lucknow, IN;
Sunil Kumar Puri, Lucknow, IN;
Guru Prasad Dutta, Lucknow, IN;
Anil Kumar Dwivedi, Lucknow, IN;
Satyawan Singh, Lucknow, IN;
Pratima Srivastava, Lucknow, IN;
Vikash Chandra Pandey, Lucknow, IN;
Sudhir Srivastava, Lucknow, IN;
Shio Kumar Singh, Lucknow, IN;
Ram Chandra Gupta, Lucknow, IN;
Jagdishwar Sahai Srivastava, Lucknow, IN;
Omkar Prasad Asthana, Lucknow, IN;
Francis Joseph Pinto, Mumbai, IN;
Swati Ajay Piramal, Mumbai, IN;
Ram Pratap, Lucknow, IN;
Amiya Prasad Bhaduri, Lucknow, IN;
Harsh Pati Thapliyal, Lucknow, IN;
Sunil Kumar Puri, Lucknow, IN;
Guru Prasad Dutta, Lucknow, IN;
Anil Kumar Dwivedi, Lucknow, IN;
Satyawan Singh, Lucknow, IN;
Pratima Srivastava, Lucknow, IN;
Vikash Chandra Pandey, Lucknow, IN;
Sudhir Srivastava, Lucknow, IN;
Shio Kumar Singh, Lucknow, IN;
Ram Chandra Gupta, Lucknow, IN;
Jagdishwar Sahai Srivastava, Lucknow, IN;
Omkar Prasad Asthana, Lucknow, IN;
Nicholas Piramal India Limited, Mumbai, IN;
Council of Scientific and Industrial Research, New Delhi, IN;
Abstract
A combination kit for the treatment of malaria caused by() having individual doses of an anti-malarial agent, 3-[1-[[4-[(6-methoxy-8-quinolinyl)amino]pentyl]amino]ethylidene]-dihydro-2(3H)-furanone (I) in the form of capsules; individual doses of the anti-malarial agent, chloroquine in the form of tablets; and instruction material for the administration of the two anti-malarial drugs. The combination kit is particularly suited for a 6 days treatment regimen where the treatment is rendered by five tablets containing 500 mg of chloroquine phosphate (equivalent to 300 mg base), three to be taken on day one and one each on days two and three; and five capsules containing 25 mg of 3-[1-[[4-[(6-methoxy-8-quinolinyl)amino]pentyl]amino]ethylidene]-dihydro-2(3H)-furanone (I), one each to be taken on days two to six.